Novo Nordisk stock jumps over 7% after weight loss drug Wegovy pill gets US FDA nod — Details here

Stock market news: Denmark-based pharmaceutical giant, Novo Nordisk, stock price jumped more than 7% during the stock market session on Tuesday, 23 December 2025, after the company's weight loss drug Wegovy pill received the US Food and Drug Administration (FDA) approval on 22 December 2025.

Novo Nordisk disclosed that the Wegovy pill, which is taken once daily, seeks to reduce the excess body weight of the person, maintain the weight cut for the long term and reduce the risk of major adverse cardiovascular issues.

“The pill is here. With today's approval of the Wegovy® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy® injection,” said Mike Doustdar, the President and CEO of Novo Nordisk.

The pharma giant also disclosed that it expects to launch the Wegovy pill in the United States by early January 2026. Novo Nordisk has also submitted for approval to the European Medicines Agency (EMA) and other regulatory authorities during the second half of 2025.

Novo Nordisk stock price today

Novo Nordisk stock jumped 7.18% to 325.30 Danish Krone (kr) during the intraday trading session in Denmark on 23 December 2025, compared to kr. 303.50 at the previous market close, MarketWatch data shows.

After touching their intraday high levels on Tuesday, the Denmark-based pharma stock was trading 6.90% higher at kr. 324.55, compared to the previous market close levels.

The company's shares hit their 52-week high level at kr. 675.20, while the 52-week low level stood at kr. 266.90, according to the market data. Novo Nordisk's market capitalisation (M-Cap) stood at kr. 1.35 trillion or around $211.7 billion as of Tuesday's market session.

Novo Nordisk stocks have given global market investors more than 52% returns on their investment in the last five years, but the company's shares have lost 47.68% in the last one-year period on the Danish stock markets.

Over the last one-month period, the pharma giant's stock has risen 13.50%, and is trading 6% higher in the last five market sessions.

Novo Nordisk ADR stock in focus

Novo Nordisk ADR stock listed on the New York Stock Exchange (NYSE) will be in focus of the US stock market investors on Tuesday, 23 December 2025, after the company's US FDA approval win.

The pharma giant's shares were trading more than 6% higher in the pre-market session on the US stock market today at $51.29, compared to its previous Wall Street close levels at $48.10, according to MarketWatch data.

The company announced the update after Monday's US stock market hours; hence, the Novo Nordisk ADR share price jumped over 10% during Monday's after-market hours trading session on Wall Street.

Read all stock market news here

Read all stories by Anubhav Mukherjee

Disclaimer: This story is for educational purposes only. We advise investors to check with certified experts before making any investment decisions.